Grunenthal to refinance €200 million bridge loan following note sale

By William Gullotti

Buffalo, N.Y., April 19 – Grunenthal GmbH said in a news release it will refinance a €200 million bridge loan put in place to partially fund its acquisition of testosterone therapy drug producer Nebido in July 2022.

The refinancing follows the sale by Grunenthal of €300 million of seven-year secured notes on Wednesday.

The company also disclosed that it had earlier extended the maturity of its €500 million revolving credit facility.

Further details regarding the revolver extension were not disclosed in the press release.

The global pharmaceutical company is based in Aachen, Germany.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.